Abstract
Summary
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
LPI (LP Information)' newest research report, the “Urokinase Injection Industry Forecast” looks at past sales and reviews total world Urokinase Injection sales in 2022, providing a comprehensive analysis by region and market sector of projected Urokinase Injection sales for 2023 through 2029. With Urokinase Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Urokinase Injection industry.
This Insight Report provides a comprehensive analysis of the global Urokinase Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Urokinase Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Urokinase Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Urokinase Injection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Urokinase Injection.
The global Urokinase Injection market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Urokinase Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Urokinase Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Urokinase Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Urokinase Injection players cover NDPHARM, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems Inc and LIVZON, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Urokinase Injection market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
10000-100000IU
100000-1000000IU
Others
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
NDPHARM
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems Inc
LIVZON
Key Questions Addressed in this Report
What is the 10-year outlook for the global Urokinase Injection market?
What factors are driving Urokinase Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Urokinase Injection market opportunities vary by end market size?
How does Urokinase Injection break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Urokinase Injection Industry Forecast” looks at past sales and reviews total world Urokinase Injection sales in 2022, providing a comprehensive analysis by region and market sector of projected Urokinase Injection sales for 2023 through 2029. With Urokinase Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Urokinase Injection industry.
This Insight Report provides a comprehensive analysis of the global Urokinase Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Urokinase Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Urokinase Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Urokinase Injection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Urokinase Injection.
The global Urokinase Injection market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Urokinase Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Urokinase Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Urokinase Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Urokinase Injection players cover NDPHARM, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems Inc and LIVZON, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Urokinase Injection market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
10000-100000IU
100000-1000000IU
Others
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
NDPHARM
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems Inc
LIVZON
Key Questions Addressed in this Report
What is the 10-year outlook for the global Urokinase Injection market?
What factors are driving Urokinase Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Urokinase Injection market opportunities vary by end market size?
How does Urokinase Injection break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Urokinase Injection Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Urokinase Injection by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Urokinase Injection by Country/Region, 2018, 2022 & 2029
2.2 Urokinase Injection Segment by Type
2.2.1 10000-100000IU
2.2.2 100000-1000000IU
2.2.3 Others
2.3 Urokinase Injection Sales by Type
2.3.1 Global Urokinase Injection Sales Market Share by Type (2018-2023)
2.3.2 Global Urokinase Injection Revenue and Market Share by Type (2018-2023)
2.3.3 Global Urokinase Injection Sale Price by Type (2018-2023)
2.4 Urokinase Injection Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Urokinase Injection Sales by Application
2.5.1 Global Urokinase Injection Sale Market Share by Application (2018-2023)
2.5.2 Global Urokinase Injection Revenue and Market Share by Application (2018-2023)
2.5.3 Global Urokinase Injection Sale Price by Application (2018-2023)
3 Global Urokinase Injection by Company
3.1 Global Urokinase Injection Breakdown Data by Company
3.1.1 Global Urokinase Injection Annual Sales by Company (2018-2023)
3.1.2 Global Urokinase Injection Sales Market Share by Company (2018-2023)
3.2 Global Urokinase Injection Annual Revenue by Company (2018-2023)
3.2.1 Global Urokinase Injection Revenue by Company (2018-2023)
3.2.2 Global Urokinase Injection Revenue Market Share by Company (2018-2023)
3.3 Global Urokinase Injection Sale Price by Company
3.4 Key Manufacturers Urokinase Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Urokinase Injection Product Location Distribution
3.4.2 Players Urokinase Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Urokinase Injection by Geographic Region
4.1 World Historic Urokinase Injection Market Size by Geographic Region (2018-2023)
4.1.1 Global Urokinase Injection Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Urokinase Injection Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Urokinase Injection Market Size by Country/Region (2018-2023)
4.2.1 Global Urokinase Injection Annual Sales by Country/Region (2018-2023)
4.2.2 Global Urokinase Injection Annual Revenue by Country/Region (2018-2023)
4.3 Americas Urokinase Injection Sales Growth
4.4 APAC Urokinase Injection Sales Growth
4.5 Europe Urokinase Injection Sales Growth
4.6 Middle East & Africa Urokinase Injection Sales Growth
5 Americas
5.1 Americas Urokinase Injection Sales by Country
5.1.1 Americas Urokinase Injection Sales by Country (2018-2023)
5.1.2 Americas Urokinase Injection Revenue by Country (2018-2023)
5.2 Americas Urokinase Injection Sales by Type
5.3 Americas Urokinase Injection Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Urokinase Injection Sales by Region
6.1.1 APAC Urokinase Injection Sales by Region (2018-2023)
6.1.2 APAC Urokinase Injection Revenue by Region (2018-2023)
6.2 APAC Urokinase Injection Sales by Type
6.3 APAC Urokinase Injection Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Urokinase Injection by Country
7.1.1 Europe Urokinase Injection Sales by Country (2018-2023)
7.1.2 Europe Urokinase Injection Revenue by Country (2018-2023)
7.2 Europe Urokinase Injection Sales by Type
7.3 Europe Urokinase Injection Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Urokinase Injection by Country
8.1.1 Middle East & Africa Urokinase Injection Sales by Country (2018-2023)
8.1.2 Middle East & Africa Urokinase Injection Revenue by Country (2018-2023)
8.2 Middle East & Africa Urokinase Injection Sales by Type
8.3 Middle East & Africa Urokinase Injection Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Urokinase Injection
10.3 Manufacturing Process Analysis of Urokinase Injection
10.4 Industry Chain Structure of Urokinase Injection
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Urokinase Injection Distributors
11.3 Urokinase Injection Customer
12 World Forecast Review for Urokinase Injection by Geographic Region
12.1 Global Urokinase Injection Market Size Forecast by Region
12.1.1 Global Urokinase Injection Forecast by Region (2024-2029)
12.1.2 Global Urokinase Injection Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Urokinase Injection Forecast by Type
12.7 Global Urokinase Injection Forecast by Application
13 Key Players Analysis
13.1 NDPHARM
13.1.1 NDPHARM Company Information
13.1.2 NDPHARM Urokinase Injection Product Portfolios and Specifications
13.1.3 NDPHARM Urokinase Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 NDPHARM Main Business Overview
13.1.5 NDPHARM Latest Developments
13.2 Wanhua Biochem
13.2.1 Wanhua Biochem Company Information
13.2.2 Wanhua Biochem Urokinase Injection Product Portfolios and Specifications
13.2.3 Wanhua Biochem Urokinase Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Wanhua Biochem Main Business Overview
13.2.5 Wanhua Biochem Latest Developments
13.3 Jiangxi Haoran Bio-Pharma
13.3.1 Jiangxi Haoran Bio-Pharma Company Information
13.3.2 Jiangxi Haoran Bio-Pharma Urokinase Injection Product Portfolios and Specifications
13.3.3 Jiangxi Haoran Bio-Pharma Urokinase Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Jiangxi Haoran Bio-Pharma Main Business Overview
13.3.5 Jiangxi Haoran Bio-Pharma Latest Developments
13.4 Jiangsu Aidea Pharmaceutical
13.4.1 Jiangsu Aidea Pharmaceutical Company Information
13.4.2 Jiangsu Aidea Pharmaceutical Urokinase Injection Product Portfolios and Specifications
13.4.3 Jiangsu Aidea Pharmaceutical Urokinase Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Jiangsu Aidea Pharmaceutical Main Business Overview
13.4.5 Jiangsu Aidea Pharmaceutical Latest Developments
13.5 Techpool
13.5.1 Techpool Company Information
13.5.2 Techpool Urokinase Injection Product Portfolios and Specifications
13.5.3 Techpool Urokinase Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Techpool Main Business Overview
13.5.5 Techpool Latest Developments
13.6 Microbic Biosystems Inc
13.6.1 Microbic Biosystems Inc Company Information
13.6.2 Microbic Biosystems Inc Urokinase Injection Product Portfolios and Specifications
13.6.3 Microbic Biosystems Inc Urokinase Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Microbic Biosystems Inc Main Business Overview
13.6.5 Microbic Biosystems Inc Latest Developments
13.7 LIVZON
13.7.1 LIVZON Company Information
13.7.2 LIVZON Urokinase Injection Product Portfolios and Specifications
13.7.3 LIVZON Urokinase Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 LIVZON Main Business Overview
13.7.5 LIVZON Latest Developments
14 Research Findings and Conclusion